RxDoctor Payments DataLook up a doctor →

Wei Wei Ma, MD

Neurology · Edison, NJNPI 1063412310

Payments from drug & device makers

$85,125in general payments, 2019–2025

Across 437 payments — averaging $194.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$35K
  • Sunovion Pharmaceuticals Inc.$31K
  • UCB, Inc.$16K
  • Livanova USA, Inc.$464
  • Argenx US, Inc.$442
  • AbbVie$402
  • plus $3K from 36 others

What the payments were for

  • Consulting fees$5,70015%
  • Speaking & faculty fees$24,06062%
  • Travel & lodging$8212%
  • Food & beverage$7,96721%
  • Education$480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$85,125 in reported general payments places this provider in the 90th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$81,197
Medicare patients
294
Services billed
570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5054$638,522
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5026$484,404
PanzygaImmun Glob G(Igg)-Ifas/Glycine33$471,848
GammakedImmune Globul G/Gly/Iga Avg 4624$221,876
AptiomEslicarbazepine Acetate53$116,749
BriviactBrivaracetam61$96,361
VimpatLacosamide12$24,570
Levetiracetam305$10,253
Lacosamide79$7,857
Mycophenolate Mofetil42$6,707
Pyridostigmine Bromide42$5,960
Divalproex Sodium ErDivalproex Sodium51$4,674
Divalproex Sodium32$2,777
Oxcarbazepine46$2,005
Lamotrigine67$1,671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$37$484,40426 claims
Kedrion Biopharma, Inc.Gammaked$15$221,87624 claims
UCB, Inc.Briviact, Vimpat$15,585$120,93173 claims
Sunovion Pharmaceuticals Inc.Aptiom$30,571$116,74953 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 521 neurology providers in New Jersey.

Other neurology in Edison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →